Waugh, Norman, Cummins, E. (Ewen), Shyangdan, Deepson S., Court, Rachel A. and Mohiuddin, Syed (2012) Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes. Manchester: National Institute for Health and Clinical Excellence (NICE). (NICE technology appraisal guidance).

Preview

Text WRAP_Waugh_Exenatide_prolonged_release.pdf - Published Version Download (287Kb) | Preview

Abstract

Prolonged-release exenatide in triple therapy regimens (that is, in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedione) is recommended as a treatment option for people with type 2 diabetes as described in 'Type 2 diabetes: the management of type 2 diabetes (NICE clinical guideline 87); that is, when control of blood glucose remains or becomes inadequate (HbA1c ≥ 7.5% [59 mmol/mol] or other higher level agreed with the individual), and the person has: a body mass index (BMI) ≥ 35 kg/m2 in those of European family origin (with appropriate adjustment for other ethnic groups) and specific psychological or medical problems associated with high body weight or a BMI < 35 kg/m2, and therapy with insulin would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.

Item Type:	Report
Subjects:	R Medicine > RC Internal medicine R Medicine > RM Therapeutics. Pharmacology
Divisions:	Faculty of Medicine > Warwick Medical School > Health Sciences
Library of Congress Subject Headings (LCSH):	Non-insulin-dependent diabetes -- Treatment
Series Name:	NICE technology appraisal guidance
Publisher:	National Institute for Health and Clinical Excellence (NICE)
Place of Publication:	Manchester
Date:	February 2012
Volume:	No.248
Number of Pages:	55
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
URI:	http://wrap.warwick.ac.uk/id/eprint/46363

Request changes to a record

Actions (login required)

View Item